January 15, 2023 • 00:12:24

Dr. Anna Casu, Associate Investigator at Translational Research Institute - AdventHealth

This episode features Dr. Anna Casu, Associate Investigator at Translational Research Institute - AdventHealth. Here, she discusses the work AdventHealth is doing with TZIELD, the first FDA approved drug that can delay the progression of Type 1 diabetes by up to three years in adults and up to eight years in children, how the screening and treatment work, what it takes to get a drug FDA approved, and more.

Loading transcript...